Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Professional use kits

This article was originally published in The Tan Sheet

Executive Summary

"In the absence of data, FDA would not consider an exemption" from the OTC labeling final rule for products intended for professional use "based solely on the addition of certain qualifying statements in the labeling," agency says in Oct. 28 letter to D.C. law firm Kleinfeld, Kaplan & Becker. FDA says it is "unaware of data or information providing evidence that granting such an exemption would not compromise the safety and effectiveness of these products." In a July 26 letter, firm sought an official FDA statement on the addition of text, such as "for hospital/professional use only," that would qualify such products for exemption from some or all OTC labeling requirements. In response, agency says exemption request's scope is unclear and law firm does not provide sufficient basis for FDA to issue guidance...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel